


# STIC CTC METABREAST

Bidard et al, Cancer Met Rev, 2012



- Primary medical endpoint: PFS (non-inferiority)
- Co-primary economical endpoint: cost/benefit ratio
- 2nd endpoints: OS, toxicities, QoL, subgroup analyses
- The study will also address what is the optimal strategy (centralized vs local CTC lab.) from the economical viewpoint